CytomX Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results. Also, BMO Capital Maintained a Market Perform Rating on the Stock and Lowered Its Price Target From $3.3 to $3.25
CytomX Therapeutics公布第四季度财务业绩后,该公司股价走低。此外,BMO Capital维持了该股的市场表现评级,并将其目标股价从3.3美元下调至3.25美元